OBJECTIVES The aim of this study was to evaluate the efficacy of various doses of post-primary percutaneous coronary intervention (PCI) bivalirudin infusion to prevent acute stent thrombosis (AST).
A bivalirudin-based anticoagulation strategy, compared with a heparin-based strategy, decreases the risk for major bleeding at the expense of an increased risk for acute stent thrombosis (AST) (4) (5) (6) (7) (8) . Therefore, in several recent randomized controlled trials (RCTs), bivalirudin infusion was continued postprimary PCI to ameliorate the risk for AST, but results have varied (7, 9, 10) . However, bivalirudin doses for post-PCI infusion therapy have been variable across these trials (11) . It appears that AST risk is mitigated by continuing the full dose of bivalirudin infusion post-PCI but not by low-dose infusion (9, 11) . To confirm this suspected trend, we performed a traditional meta-analysis using moderator analyses and a network metaanalysis using mixed-treatment comparison models to evaluate the efficacy of various doses of post-PCI bivalirudin infusion to prevent AST (12) .
METHODS STUDY DESIGN. This meta-analysis was performed according to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses guidelines for systematic reviews and meta-analyses (13) . A computerized review of PubMed, ClinicalTrials.gov, and the Cochrane Library databases was conducted to locate relevant studies. In addition, abstracts from major international cardiology scientific meetings were reviewed.
The following keywords were used: "bivalirudin," "heparin," "stent thrombosis," "percutaneous coronary intervention," and "ST-segment elevation myocardial infarction." Trials were included if they enrolled subjects with acute STEMI undergoing primary PCI and randomly assigned patients to treatment with bivalirudin or heparin. In the case of BRIGHT (Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial), which included both STEMI and non-STEMI patients, only STEMI subgroup data were used, but for MATRIX (Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trials, overall data were included because the event rates for subgroups has not yet been reported (7, 10) . The BRAVE (Bavarian Reperfusion Alternatives Evaluation)-4 trial was not included in this metaanalysis, because the event rate for AST was not reported (14) .
In those trials, 1 of 2 dosage rates of bivalirudin (1.75 or 0.25 mg/kg/h, termed Biv-Full and Biv-Low, respectively) was used for post-PCI infusion. Therefore, we divided patients into 3 groups: those receiving Biv-Full, those receiving Biv-Low, and those for whom bivalirudin infusion was stopped at the end of PCI, termed Biv-No. The primary efficacy endpoint was definite AST, defined as stent thrombosis within 24 h of primary PCI. The primary safety endpoint was the 30-day incidence of major bleeding, defined according to each trial. The secondary efficacy endpoint was subacute stent thrombosis, defined as stent thrombosis occurring more than 24 h, but <30 days, after primary PCI. In all included trials, an independent clinical events committee whose members were unaware of study group assignments adjudicated bleeding episodes and stent thrombosis.
STATISTICAL ANALYSIS. The traditional metaanalysis was performed according to the Comprehensive Meta-Analysis system version 3 (Biostat, Englewood, New Jersey). Pooled risk ratios (RRs) were calculated using a random-effects model.
Moderator analysis was performed to examine the impact of various doses of bivalirudin post-PCI on the rate of AST. We evaluated the presence of heterogeneity across trials using the Cochran Q test and from heterogeneity between studies, rather than the sampling error (15) . When heterogeneity was discovered, sensitivity analysis was performed, where 1 study at a time was excluded, and the impact on the summary results of removing each was evaluated (16) . Publication bias was not assessed, because the number of included trials was inadequate (<10) to properly assess a funnel plot or to use more advanced regression-based assessments (17) .
Bayesian network meta-analysis was performed using random-effects models because it is the most conservative methodology to account for betweentrial heterogeneity (12) . All analyses were performed using WinBUGs Bayesian software package and Net-
Ontario, Canada) (18) . We estimated the relative ranking probability of each treatment and obtained the treatment hierarchy of competing interventions using a league table and surface under the cumulative ranking curve (18) . Inconsistency was assessed by estimate of each study is marked with a square. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. The larger the square, the greater the study contribution to the overall estimate. Diamond indicates overall summary estimate for the analysis (width of the diamond represents the 95% confidence interval).
Trial acronyms as in Table 1 .
comparing the deviance residuals and deviance information criterion statistics in fitted consistency and inconsistency models (18) . (Figure 3) .
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At treatment ranking, Biv-Full ranked as the best therapy, followed closely by heparin (Online Figure 3) .
On the basis of the surface under the cumulative ranking curve values derived from trials included in our network meta-analysis, Biv-Full had an 83% probability of being ranked as the best therapy for AST prevention, while the probability for heparin was 82%. The probabilities for Biv-No and Biv-Low were 25% and 8%, respectively. We did not detect inconsistency among the trials. However, antithrombotic agents can also cause bleeding, which is strongly associated with early and late mortality (21, 22) . Thus, balancing the antiischemic benefits against the bleeding risk of these agents is of paramount importance in assessing new estimate of each study is marked with a square. The size of the square represents the weight that the corresponding study exerts in the meta-analysis. The larger the square, the greater the study contribution to the overall estimate. Diamond indicates overall summary estimate for the analysis (width of the diamond represents the 95% confidence interval).
Trial acronyms as in Table 1 . reflect an exaggerated therapeutic effect relative to a multicenter trial (20, 27) . Prior analyses have suggested that the HEAT-PPCI trial may be a major outlier in this regard (8, 28) . Therefore, in our sensitivity analysis, excluding HEAT-PPCI made all 3 bivalirudin groups significantly more effective in decreasing the bleeding risk compared with heparin (Online Figure 4) .
STUDY LIMITATIONS. First, in the majority of these trials, the patients were not randomized to receive or not receive a post-procedure PCI bivalirudin infusion.
Thus, we cannot state with certainty whether postprocedure Biv-Full infusion was responsible for the lower rates of AST risk. Therefore, our findings should be interpreted cautiously. Additional RCTs are needed to confirm these findings. E-mail: shahcardiology@yahoo.com.
